DE3170913D1 - Vaccinal complex containing a specific antigen and vaccine containing it - Google Patents

Vaccinal complex containing a specific antigen and vaccine containing it

Info

Publication number
DE3170913D1
DE3170913D1 DE8181400258T DE3170913T DE3170913D1 DE 3170913 D1 DE3170913 D1 DE 3170913D1 DE 8181400258 T DE8181400258 T DE 8181400258T DE 3170913 T DE3170913 T DE 3170913T DE 3170913 D1 DE3170913 D1 DE 3170913D1
Authority
DE
Germany
Prior art keywords
specific antigen
vaccinal
vaccine
complex
complex containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8181400258T
Other languages
German (de)
English (en)
Inventor
D Hinterland Lucien D Dussourd
Gerard Normier
Anne-Marie Pinel
Jacques Durand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre SA
Original Assignee
Pierre Fabre SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre SA filed Critical Pierre Fabre SA
Application granted granted Critical
Publication of DE3170913D1 publication Critical patent/DE3170913D1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8181400258T 1980-02-20 1981-02-19 Vaccinal complex containing a specific antigen and vaccine containing it Expired DE3170913D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8003707A FR2475900A1 (fr) 1980-02-20 1980-02-20 Complexe vaccinal contenant un antigene specifique et vaccin le contenant

Publications (1)

Publication Number Publication Date
DE3170913D1 true DE3170913D1 (en) 1985-07-18

Family

ID=9238765

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8181400258T Expired DE3170913D1 (en) 1980-02-20 1981-02-19 Vaccinal complex containing a specific antigen and vaccine containing it

Country Status (10)

Country Link
US (1) US4460575A (enExample)
EP (1) EP0035429B1 (enExample)
JP (1) JPS56131523A (enExample)
AT (1) ATE13741T1 (enExample)
AU (1) AU543201B2 (enExample)
CA (1) CA1181691A (enExample)
DE (1) DE3170913D1 (enExample)
ES (1) ES500567A0 (enExample)
FR (1) FR2475900A1 (enExample)
ZA (1) ZA811125B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870053A (en) * 1980-09-19 1989-09-26 Roussel Uclaf Novel compositions and processes
US5601984A (en) * 1983-01-10 1997-02-11 Gen-Probe Incorporated Method for detecting, the presense or amount of a taxonomic group of organisms using specific R-RNA subsequences as probes
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4692332A (en) * 1985-01-18 1987-09-08 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US5346999A (en) * 1985-01-18 1994-09-13 Applied Biosystems, Inc. Method of nucleic acid extraction
US4689222A (en) * 1985-01-18 1987-08-25 Mcmichael John Methods and materials for alleviation of pain symptoms of malignant neoplasia
US4873090A (en) * 1985-03-27 1989-10-10 Broncostat Pty. Limited Non-adjuvenated vaccine
WO1986006279A1 (en) * 1985-04-30 1986-11-06 Scripps Clinic And Research Foundation Acute phase protein modulating endotoxic activity of lipopolysaccharides, compositions and methods
US4701323A (en) * 1985-10-23 1987-10-20 Iowa State University Research Foundation, Inc. Vaccines for counteracting inhibition of neutrophil degranulation
US4681761A (en) * 1985-10-24 1987-07-21 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine
FR2619122B1 (fr) * 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
CA2049548C (en) * 1990-08-20 2002-07-02 Kiyoshi Yoshimura Lps-producing bacteria, lpss, and lps-containing medicines and veterinary medicines
US7279162B1 (en) * 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5506129A (en) * 1991-05-24 1996-04-09 Evans Medical Limited Virus production
JPH09163896A (ja) * 1995-12-13 1997-06-24 Sumitomo Pharmaceut Co Ltd 胸膜炎病態モデル動物
FR2745186B1 (fr) * 1996-02-26 1998-12-31 Torossian Fernand Narbey Complexe immunomodulateur et ses utilisations pour le traitement et la prevention des recidives des affections par helicobacter
DE19703437A1 (de) * 1997-01-30 1998-08-06 Luitpold Pharma Gmbh Gemische äußerer Membranen und/oder Zellwände von Bakterien zur oralen Immunisierung gegen Schleimhautinfektionen
GB2325233B (en) * 1997-05-16 2001-07-18 Norsk Hydro As Substrates having bound polysaccharides and bacterial nucleic acids
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
PT1588716E (pt) 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Conjugados de peg-urato oxidase e sua utiliza??o
AU2001288961A1 (en) * 2000-09-12 2002-06-18 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
GB2370839A (en) * 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
GB2370838A (en) * 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex
CA2463008A1 (en) * 2001-10-26 2003-07-24 Id Biomedical Corporation Of Washington Efficient protein expression system
WO2006110761A2 (en) * 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
LT3321359T (lt) 2005-04-11 2021-05-10 Horizon Pharma Rheumatology Llc Urato oksidazės variantinės formos ir jų panaudojimas
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
PL398781A1 (pl) 2009-06-25 2012-11-19 Savient Pharmaceuticals, Inc. Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
JP7611465B2 (ja) * 2019-10-10 2025-01-10 ジェイ・アイ・サイエンス有限会社 溶離液性の利用フラクションコレクター
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
FR2253499B1 (enExample) * 1973-12-10 1977-11-04 Fabre Sa Pierre
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
FR2305990A1 (fr) * 1975-04-02 1976-10-29 Fabre Sa Pierre Preparation de vaccins a base d'acides nucleiques arn associes a des polysaccharides extraits de germes microbiens
FR2360314A2 (fr) * 1976-08-06 1978-03-03 Fabre Sa Pierre Nouveaux vaccins perfectionnes a base de fractions ribosomales
FR2374911A1 (fr) * 1976-12-21 1978-07-21 Fabre Sa Pierre Adjuvants d'immunite non specifique
FR2388563A1 (fr) * 1977-04-29 1978-11-24 Fabre Sa Pierre Vaccins acellulaires perfectionnes contenant des polysaccharides capsulaires
US4285930A (en) * 1977-12-08 1981-08-25 Likhite Vilas V Antigens comprising immunostimulant adjuvants and their use in immunotherapy

Also Published As

Publication number Publication date
ZA811125B (en) 1982-03-31
EP0035429A1 (fr) 1981-09-09
CA1181691A (en) 1985-01-29
ATE13741T1 (de) 1985-06-15
ES8203226A1 (es) 1982-04-16
AU543201B2 (en) 1985-04-04
EP0035429B1 (fr) 1985-06-12
US4460575A (en) 1984-07-17
FR2475900B1 (enExample) 1983-06-10
JPS56131523A (en) 1981-10-15
AU6750181A (en) 1981-08-27
ES500567A0 (es) 1982-04-16
FR2475900A1 (fr) 1981-08-21

Similar Documents

Publication Publication Date Title
DE3170913D1 (en) Vaccinal complex containing a specific antigen and vaccine containing it
PH20502A (en) Quarternary 6,11-dihydro-dibenzo-(b,e)-thiepine-11-n-alkyl-norscopine ethers
IT1141258B (it) Metodo per ridurre il numero di microorganismi in un mezzo,e metodo di preservazione
EP0121249A3 (en) Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine
NL300401I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
IL65835A (en) Protozoal antigen,its preparation and vaccine containing it
JPS57116100A (en) Novel d-homosteroid
DE3064090D1 (en) Babesiosis antigen, vaccine and diagnostic reagent comprising it
PH17260A (en) Geothermal brine treatment
FR2471785B1 (enExample)
IL65496A0 (en) Protozoal antigen,its preparation and vaccine containing it
IL59663A0 (en) Vaccines obtained from bacterial mutant strains
ZA905927B (en) Biological preparation and its use
IL70069A0 (en) Novel strains of azospirillum,methods of growing the strains,compositions containing them and use thereof as biofertilizer
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
GR73033B (enExample)
IL58677A0 (en) Process for the preparation of 1 ,3 -dihydroxy- -steroids and intermediates useful in the process
JPS54154506A (en) Vaccine for cancer immunological treating method
EP0309898A3 (en) Method for the induction of a cytotoxic t cell response
GB2144129B (en) Antigens as immunostimulant adjuvants
JPS54140715A (en) Vaccine stabilizer
Macoosh Algebraic closures for commutative rings
IL57838A0 (en) N-cyclohexyl-n-methoxyacetamide,its preparation and its use in the preparation of o-methyl-n-cyclohexyl-2,5-dimethylfuran-3-hydroxamic acid
GB2029222B (en) Antigenic material for the prevention or reduction of fly strike in sheep
GB2127694B (en) Improvements in or relating to autoclaves

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PIERRE FABRE S.A., BOULOGNE, FR